Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
about
Current and emerging strategies for the prevention of graft-versus-host diseaseThe Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical OverviewChimeric antigen receptor-modified T cells for acute lymphoid leukemiaLung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantationInterleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.The biology of graft-versus-host disease: experimental systems instructing clinical practice.Aqueous two-phase systems enable multiplexing of homogeneous immunoassays.Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levelsTargeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality.Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of diseaseJanus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationAlpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunityDonor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation.Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease.Advances in understanding the pathogenesis of graft-versus-host disease.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.Role of the intestinal mucosa in acute gastrointestinal GVHD.Tocilizumab for steroid refractory acute graft-versus-host diseaseST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.Influence of donor microbiota on the severity of experimental graft-versus-host-disease.Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationProteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.Tocilizumab for the treatment of steroid refractory graft-versus-host disease.Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.Neddylation plays an important role in the regulation of murine and human dendritic cell function.A Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children.Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation.Role of STAT3 in regulatory T lymphocyte plasticity during acute graft-vs.-host-diseaseCombined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Regulatory T cells and IL-17-producing cells in graft-versus-host disease.Immunotherapeutic implication of IL-6 blockade.GVHD prevention: an ounce is better than a pound.
P2860
Q27016541-202790D5-6CB4-41B5-8AB0-C122A4FDCE2EQ28066083-7D718EA2-17EF-49B7-ACC2-978182F51856Q29620130-E3B61032-6290-4481-9CDB-1217B9B2D5CAQ33758318-36EB19F5-F9A3-4410-AA5B-079836619553Q33774610-79984A1D-D2D3-4A24-8271-99AB66FA15A8Q33917175-D7BB892E-BD4C-4ABF-BF2E-C6FA7155C049Q33965654-D8D94FC5-41BA-4BED-ADA3-B67028ED9C49Q34624143-8DB4F048-4172-416B-B739-84BBB13AB91FQ35067377-4179C169-D0AC-4D93-9034-EEBA082B1933Q35483838-991B3776-D0ED-4609-9B69-E317F1CC5EC7Q35553626-3DC5D539-2EEF-4DAB-8872-3D6ADB96A1FFQ35553632-D318ED4C-9F73-4F60-B1E0-2CE20246E8C4Q35563471-0B35F9A2-5D39-45A9-8A0A-B2E5194B01FBQ35586614-5E48421C-5422-499B-A93B-1824490CAD5FQ35673668-48BB37AF-5621-4199-AB4A-0BC203BBAEA9Q35691842-7FC9E348-9F59-4FF3-9465-42332536AA01Q35865094-51640213-9C81-4E30-BC31-19D608404DEEQ35883325-ECB41166-05E4-49AF-A728-59514DA1748AQ35894369-CA9A141E-BD7F-49FB-9BBA-8EF97AEF9C6BQ35971439-EB5DDDBF-2A74-4A72-8236-7F2BD0500D20Q36130498-57A4BF5B-6C35-4765-A5B6-B6AAC788A64BQ36202472-4584A289-05C1-4A0A-843B-95156E7B2A77Q36212428-B391E90A-0BC7-42EC-9032-9F40E951E53BQ36422339-C2D0BCC4-D8C7-4E44-9822-B1F8EC0C4226Q36424657-168FE14B-EB66-4FC7-BB6A-F36E3A01AFF0Q36487338-454F24FF-4420-4C4C-B944-5B2514334E7AQ36675086-A5B28924-48FF-48AD-935E-59DB1B8EF9DFQ36891433-0F5C8356-8D93-4A84-A473-A90D73EC428BQ36904560-D7F509BC-253F-42D8-800B-D77198456BCFQ37026278-5B5D51D6-5BCC-4E6A-8C3E-068D255BC5CFQ37035815-9AE445CA-CF56-459D-A331-74CBECD6F5E7Q37080218-06B4E035-B8E7-4860-9E93-60D32A248348Q37186465-F0801C44-C556-4CCB-A502-2E5F3EC748B6Q37276584-86699401-FD08-4984-B0BE-398D5536786AQ37465452-469EC1F9-3584-4D0D-8959-9318E91E8F9AQ37529686-588D2E07-045A-4017-BEC4-089ACF48D38DQ37603497-06CCF756-273C-49DB-9312-D00690592B29Q37900645-959C08A1-79DE-4325-B8B6-B907473D1E1EQ37965754-B14BA76F-E564-4FCC-A974-5DE34E7828DCQ37973859-E61A60EC-DDE7-4C41-B718-ED8A1D7CB713
P2860
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@ast
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@en
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@nl
type
label
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@ast
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@en
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@nl
prefLabel
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@ast
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@en
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@nl
P2093
P2860
P1476
Interleukin-6 modulates graft- ...... c bone marrow transplantation.
@en
P2093
Chelsea Malter
Dafydd Thomas
Evelyn Nieves
Geoffrey R Hill
Isao Tawara
Kathleen P Lowler
Motoko Koyama
Norihiro Nishimoto
Pavan Reddy
P2860
P356
10.1158/1078-0432.CCR-10-1198
P407
P577
2010-11-03T00:00:00Z